Loading company
Atyr Pharma Inc.
ATYR · Nasdaq · ·
Next earnings: November 5, 2026
$0.31+3.8%Sep 29 close
- 1M
- -35.3%
- 6M
- -63.8%
- 1Y
- -55.3%
- 5Y
- -96.9%
ATYR · Nasdaq · ·
Next earnings: November 5, 2026
$0.31+3.8%Sep 29 close
Atyr Pharma Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$10.3M | -$19.5M | +47.22% |
| Profit per share | -$0.11 | -$0.22 | +50.00% |
| Free Cash Flow | -$9.4M | -$13.9M | +32.22% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We are proactively taking decisive, necessary action to focus our resources on our lead therapeutic candidate, efzofitimod, as we await feedback from the FDA on the protocol we submitted for our planned Phase 3 study in pulmonary sarcoidosis patients with restrictive lung disease. This approach positions aTyr to advance this planned Phase 3 study efficiently and continue completing the Phase 2 EFZO-CONNECT study in SSc-ILD,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from Atyr Pharma Inc.’s Item 2.02 8-K filed August 7, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Atyr Pharma Inc. has no earnings call transcript available.